NASDAQ:JYNT Joint - JYNT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $16.39 -0.03 (-0.18%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.87▼$16.4050-Day Range$14.92▼$19.5652-Week Range$12.85▼$37.52Volume74,472 shsAverage Volume123,777 shsMarket Capitalization$238.15 millionP/E Ratio204.88Dividend YieldN/APrice Target$32.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Joint MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside100.3% Upside$32.83 Price TargetShort InterestBearish7.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 2 Articles This WeekInsider TradingAcquiring Shares$542,560 Bought Last QuarterProj. Earnings Growth100.00%From $0.12 to $0.24 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector493rd out of 1,005 stocksPatent Owners & Lessors Industry4th out of 7 stocks 3.3 Analyst's Opinion Consensus RatingJoint has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.83, Joint has a forecasted upside of 100.3% from its current price of $16.39.Amount of Analyst CoverageJoint has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.50% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Joint has recently increased by 0.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JYNT. Previous Next 1.1 News and Social Media Coverage News SentimentJoint has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Joint this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for JYNT on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Joint to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Joint insiders have bought more of their company's stock than they have sold. Specifically, they have bought $542,560.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Joint is held by insiders.Percentage Held by Institutions88.13% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Joint are expected to grow by 100.00% in the coming year, from $0.12 to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is 204.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 123.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is 204.88, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 124.73.Price to Book Value per Share RatioJoint has a P/B Ratio of 7.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Joint (NASDAQ:JYNT) StockThe Joint Corp. engages in the development, ownership, operation, support, and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment consists of the operating activities of the company-owned or managed clinics. The Franchise Operations segment includes the operating activities of the franchise business unit. The Joint was founded by Fred Gerretzen, Charles Barnwell, John Leonesio, Todd Welker, Barbara Holland, Steven P. Colmar, Craig P. Colmar, and Richard Rees on March 10, 2010 and is headquartered in Scottsdale, AZ.Read More Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Stock News HeadlinesMarch 22, 2023 | finance.yahoo.comThe Joint (JYNT) to Enter Puerto Rico With New Franchise DealMarch 17, 2023 | finance.yahoo.comMilitary Husband and Wife Team Set to Expand The Joint Chiropractic into Puerto RicoMarch 26, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 13, 2023 | finance.yahoo.comThe Joint Corp. (NASDAQ:JYNT) Q4 2022 Earnings Call TranscriptMarch 13, 2023 | finance.yahoo.comThe Joint Corp. Thanks Retiring Board Member James H. Amos, Jr.March 9, 2023 | finance.yahoo.comThe Joint Corp. Reports Fourth Quarter and Year-end 2022 Financial ResultsMarch 9, 2023 | finance.yahoo.comThe Joint Corp. (JYNT) Misses Q4 Earnings EstimatesMarch 6, 2023 | finance.yahoo.comThe Joint Corp. to Participate in the 35th Annual Roth ConferenceMarch 26, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 28, 2023 | finance.yahoo.comThe Joint Corp. (NASDAQ:JYNT) is a favorite amongst institutional investors who own 63%February 23, 2023 | finance.yahoo.comThe Joint Corp. to Host Conference Call on Thursday, March 9th to Discuss Fourth Quarter 2022 ResultsFebruary 8, 2023 | finance.yahoo.comThe Joint Corp. (NASDAQ:JYNT) Shares Could Be 44% Below Their Intrinsic Value EstimateFebruary 1, 2023 | finance.yahoo.comThe Joint's Annual "Love The Joint" Giveaway Returns to Give the Gift of Free ChiropracticJanuary 30, 2023 | finance.yahoo.comThe Joint Chiropractic Captures Recognition on the Annual 'Fast & Serious' Brand RankingJanuary 27, 2023 | finance.yahoo.comThe Joint Chiropractic Climbs the Entrepreneur 500 RankingJanuary 26, 2023 | finance.yahoo.comThe Joint Chiropractic Earns Major Accolades for Franchising ExcellenceJanuary 18, 2023 | finance.yahoo.comThe 14% return this week takes Joint's (NASDAQ:JYNT) shareholders five-year gains to 273%January 17, 2023 | finance.yahoo.comThe Joint Chiropractic Boasts Top Tier FUND Score for Franchise FinancingJanuary 17, 2023 | msn.comThe Joint (JYNT) 2022 Visits Grow to 12.2M, Adds New ClinicsJanuary 12, 2023 | finance.yahoo.comThe Joint Corp. Reports 2022 Operating MetricsJanuary 5, 2023 | finance.yahoo.comThe Joint Corp. Introduces New Chief Human Resources OfficerJanuary 3, 2023 | finance.yahoo.comThe Joint Corp. Increases Corporate Portfolio to 126 ClinicsJanuary 2, 2023 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About The Joint Corp. (NASDAQ:JYNT)?December 8, 2022 | finance.yahoo.comThe Joint Corp. to Participate in the 11th Annual ROTH Deer Valley EventDecember 6, 2022 | finance.yahoo.comThe Joint Chiropractic Expands to Alaska, Signs Franchise Agreement for Three ClinicsNovember 17, 2022 | finance.yahoo.comThe Joint Chiropractic Ranks 198 on Franchise Times' Exclusive Top 500 Annual ListNovember 14, 2022 | finance.yahoo.comRealign Holiday Health with The Joint Chiropractic's "Back Friday" DealsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Company Calendar Last Earnings11/04/2021Today3/26/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Patent owners & lessors Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JYNT CUSIPN/A CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees316Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.83 High Stock Price Forecast$50.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+100.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio204.88 Forward P/E Ratio136.58 P/E GrowthN/ANet Income$1.18 million Net Margins1.15% Pretax Margin1.91% Return on Equity3.79% Return on Assets1.34% Debt Debt-to-Equity Ratio0.06 Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual Sales$101.91 million Price / Sales2.34 Cash Flow$0.61 per share Price / Cash Flow27.05 Book Value$2.23 per share Price / Book7.35Miscellaneous Outstanding Shares14,530,000Free Float14,021,000Market Cap$238.15 million OptionableNot Optionable Beta1.35 Key ExecutivesPeter D. HoltPresident, Chief Executive Officer & DirectorJorge ArmenterosSenior Vice President-OperationsJacob SingletonChief Financial Officer & ControllerCharles NellesChief Technology OfficerSteve KnaufVice President-Chiropractic & ComplianceKey CompetitorsAurora CannabisNYSE:ACB908 DevicesNASDAQ:MASSInnate PharmaNASDAQ:IPHAAlpine Immune SciencesNASDAQ:ALPNSurmodicsNASDAQ:SRDXView All CompetitorsInsiders & InstitutionsAlliancebernstein L.P.Bought 2,618 shares on 2/16/2023Ownership: 0.152%White Pine Capital LLCSold 632 shares on 2/16/2023Ownership: 0.125%State of WyomingBought 6,736 shares on 2/16/2023Ownership: 0.065%Legal & General Group PlcSold 2,953 shares on 2/15/2023Ownership: 0.216%Algert Global LLCSold 5,842 shares on 2/15/2023Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions JYNT Stock - Frequently Asked Questions Should I buy or sell Joint stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JYNT shares. View JYNT analyst ratings or view top-rated stocks. What is Joint's stock price forecast for 2023? 4 analysts have issued 12 month target prices for Joint's shares. Their JYNT share price forecasts range from $15.00 to $50.00. On average, they anticipate the company's share price to reach $32.83 in the next year. This suggests a possible upside of 100.3% from the stock's current price. View analysts price targets for JYNT or view top-rated stocks among Wall Street analysts. How have JYNT shares performed in 2023? Joint's stock was trading at $13.98 at the start of the year. Since then, JYNT stock has increased by 17.2% and is now trading at $16.39. View the best growth stocks for 2023 here. When is Joint's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our JYNT earnings forecast. How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) announced its quarterly earnings data on Thursday, November, 4th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.09. The company earned $20.99 million during the quarter, compared to the consensus estimate of $19.48 million. Joint had a trailing twelve-month return on equity of 3.79% and a net margin of 1.15%. During the same period in the prior year, the company earned $0.11 earnings per share. What ETFs hold Joint's stock? ETFs with the largest weight of Joint (NASDAQ:JYNT) stock in their portfolio include Changebridge Capital Sustainable Equity ETF (CBSE), Changebridge Capital Long/Short Equity ETF (CBLS), Janus Henderson Small Cap Growth Alpha ETF (JSML) and Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) and What guidance has Joint issued on next quarter's earnings? Joint updated its FY 2023 earnings guidance on Thursday, March, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $123.00 million-$128.00 million, compared to the consensus revenue estimate of $121.34 million. What is Peter D. Holt's approval rating as Joint's CEO? 87 employees have rated Joint Chief Executive Officer Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among the company's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), Salesforce (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE). When did Joint IPO? (JYNT) raised $20 million in an initial public offering on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager. What is Joint's stock symbol? Joint trades on the NASDAQ under the ticker symbol "JYNT." Who are Joint's major shareholders? Joint's stock is owned by many different institutional and retail investors. Top institutional investors include Bandera Partners LLC (17.41%), Millennium Management LLC (3.87%), Morgan Stanley (3.43%), Skylands Capital LLC (3.07%), Geode Capital Management LLC (1.80%) and Two Sigma Investments LP (1.24%). Insiders that own company stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel, Peter D Holt and Ronald V Davella. View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Joint's stock price today? One share of JYNT stock can currently be purchased for approximately $16.39. How much money does Joint make? Joint (NASDAQ:JYNT) has a market capitalization of $238.15 million and generates $101.91 million in revenue each year. The company earns $1.18 million in net income (profit) each year or $0.08 on an earnings per share basis. How many employees does Joint have? The company employs 316 workers across the globe. How can I contact Joint? Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The official website for the company is www.thejoint.com. The company can be reached via phone at (480) 245-5960, via email at thejoint@lhai.com, or via fax at 480-513-7989. This page (NASDAQ:JYNT) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.